Former U.S. President Donald Trump has made headlines once again with a bold pledge: to slash prescription drug prices by an astonishing 1,500%. While the claim has generated buzz among his supporters and sparked debate across the political spectrum, the sheer scale of the number has left many experts, analysts, and everyday Americans questioning exactly what such a figure means, whether it is mathematically possible, and how it might be achieved in practice.
At first glance, the claim grabs attention. The cost of medications has been a continuous concern for countless people in the United States, impacting not only those requiring treatment but also insurance companies, medical centers, and government financial plans. The notion of significantly reducing drug costs is attractive, especially for individuals who find it challenging to pay for essential treatments every month. Nonetheless, when the reduction percentage is more than the entire price of the item itself—as suggested by a claim of “1,500% reduction”—it naturally prompts inquiries about the preciseness and purpose of such a statement.
To assess the practicality of such a claim, examining the mathematics is crucial. In simple terms, a complete 100% reduction means the product would have no cost. Exceeding this—especially achieving 1,500%—is inconsistent with traditional pricing principles. A decrease of 1,500% implies not only removing the cost altogether but also compensating consumers multiple times for acquiring the medication, which is not a standard procedure in any market, particularly not in the pharmaceutical sector.
This has led observers to believe that the figure may be more rhetorical than literal, intended to emphasize the severity of Trump’s dissatisfaction with current pricing structures rather than to serve as a mathematically precise policy proposal. Trump has a history of using hyperbolic language to capture attention and frame policy debates, and this statement appears to follow that pattern.
Still, underneath the exaggerated figure lies a real and ongoing policy issue: the exceptionally high cost of prescription medications in the United States compared to other developed countries. The U.S. pharmaceutical market is unique in that it allows for drug prices to be set largely by manufacturers, without government-imposed caps seen in countries with single-payer systems or more aggressive price negotiation frameworks. As a result, some drugs cost several times more in the U.S. than they do elsewhere, leading to public outrage and increasing calls for reform.
Trump’s past actions concerning drug pricing provide some understanding of how he could tackle the issue if he has the chance. While he was in office, he advocated for a “most favored nation” rule aimed at linking U.S. drug costs to the less expensive rates paid by other affluent countries. Nevertheless, this plan encountered significant opposition from the pharmaceutical sector and was eventually halted by the courts. Additionally, he issued executive orders designed to permit the import of specific medicines from Canada, due to their reduced costs. However, these efforts encountered logistical and legal challenges that hindered their broad execution.
The 1,500% figure, then, is best understood in the context of Trump’s broader political strategy. By making an extreme promise, he positions himself as a champion for consumers while casting his opponents—whether they be Democrats, industry executives, or bureaucrats—as defenders of an unjust system. The reality, however, is that any serious reduction in drug prices would require cooperation between Congress, regulatory agencies, and the pharmaceutical industry, as well as significant changes to patent law, pricing transparency rules, and Medicare’s negotiating power.
Economic experts warn that while aggressive price cuts could lower costs for patients in the short term, they could also have unintended consequences. The pharmaceutical industry often argues that high drug prices help fund research and development, enabling the creation of new treatments. A drastic reduction in revenue, they contend, could slow innovation and reduce the number of new drugs brought to market. Critics of this argument counter that much of the industry’s R&D budget is funded by taxpayers through grants and government-backed research programs, and that drug companies often spend more on marketing than on developing new treatments.
For patients, the stakes are tangible and immediate. Many Americans ration medications, skip doses, or go without treatment altogether because of high costs. In life-or-death cases—such as insulin for diabetics or chemotherapy drugs for cancer patients—unaffordable prices can have devastating consequences. The public’s frustration is not unfounded, and politicians of both parties have recognized the political potency of promising relief.
Trump’s recent declaration resonates with this discontent but omits many specifics. Which medications would be impacted by these substantial price decreases? Would the price reductions affect brand-name medications, generics, or both categories? How would the government implement these reductions within a predominantly private, market-oriented healthcare framework? Without addressing these queries, the pledge seems more like a headline-grabbing announcement than a solid policy proposal.
Here’s the text in English, following your guidelines:
The political equation is straightforward: the issue of drug costs resonates across party lines, providing a potent theme for electoral campaigns. However, implementing changes is significantly more challenging. Previous initiatives to reform the system have faltered due to the sway of pharmaceutical lobbyists, the intricacy of American healthcare regulations, and the worldwide characteristics of the drug supply chain. Any decisive action on pricing would probably encounter prolonged legal disputes and opposition in the political arena.
Currently, minor and gradual changes have proven to be somewhat effective. The Inflation Reduction Act, enacted during President Biden’s term, introduced policies enabling Medicare to discuss prices for specific expensive medications for the first time and imposed limits on insulin costs for the elderly. Although these changes are less comprehensive than Trump’s expansive language, they signify concrete progress toward making healthcare more affordable.
Whether Trump’s 1,500% promise is remembered as a serious policy idea, a rhetorical flourish, or simply campaign theater will depend on how it is developed in the months ahead. For now, it stands as an example of how political language can blur the lines between ambition and reality—especially on issues as deeply personal and financially burdensome as the cost of medicine.
The core issue is that people in the United States spend much more on prescription medications than those in similar countries, and resolving this inequality will demand a comprehensive, ongoing strategy. Be it via negotiation, regulation, or overhauling the pharmaceutical industry, the aim to reduce expenses is a common objective. The difficulty is transitioning from ambitious commitments to practical, legally viable, and economically feasible remedies—something no government, whether Republican or Democrat, has completely succeeded in accomplishing.
